MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$36,200K
EPS
-$14.6
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue-Development Fee And Royalty
-
-
0*
-
Total revenue
-
-
0*
-
Research and development
65,503
60,411
98,150*
45,247
General and administrative
16,136
15,230
12,763*
11,641
Acquired in-process research and development
-
-
0*
-
Loss on sale of in-process research and development asset
40,000
30,000
-5,000*
0
Total operating expenses
41,639
45,641
115,912*
56,888
Loss from operations
-41,639
-45,641
-115,912*
-56,888
Interest income
10,053
6,995
8,006*
5,379
Change in fair value of forward contract liability-Forward Contracts
-
-
0*
-
Other (expense) income, net
-4,614
-30,359
-30,045*
40,326
Total other income (expense)
5,439
-23,364
-22,040*
45,705
Loss before income tax expense
-36,200
-69,005
-137,953*
-11,183
Income tax benefit
0
0
-15*
0
Net loss
-36,200
-69,005
-137,938
-11,183
Basic EPS
-14.6
-29.66
-398.613
-5.97
Diluted EPS
-14.6
-29.66
-398.613
-5.97
Basic Average Shares
346,045
346,045
346,045*
346,045
Diluted Average Shares
346,045
346,045
346,045*
346,045
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$36,200K
(-10970.34%↓ Y/Y)
Interest income
$10,053K
(71.14%↑ Y/Y)
Loss before income
tax expense
-$36,200K
(1.41%↑ Y/Y)
Total other income
(expense)
$5,439K
(4.24%↑ Y/Y)
Other (expense)
income, net
-$4,614K
(-603.35%↓ Y/Y)
Loss from operations
-$41,639K
(0.71%↑ Y/Y)
Total operating
expenses
$41,639K
(-0.71%↓ Y/Y)
Loss on sale of
in-process research and...
$40,000K
(300.00%↑ Y/Y)
Research and development
$65,503K
(63.17%↑ Y/Y)
General and
administrative
$16,136K
(36.86%↑ Y/Y)
Buy us a coffee
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)